Intravitreal Bevacizumab (Avastin) as an Adjuvant for the Treatment of Posterior Scleritis.
10.3341/kjo.2011.25.4.282
- Author:
Ji Won LIM
1
;
Joo Hyun PARK
Author Information
1. Department of Ophthalmology, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea. jiwoneye@hallym.or.kr
- Publication Type:Case Report
- Keywords:
Bevacizumab;
Posterior scleritis;
Vascular endothelial growth factor
- MeSH:
Aged;
Angiogenesis Inhibitors/administration & dosage;
Antibodies, Monoclonal, Humanized/*administration & dosage;
Aqueous Humor/metabolism;
Diagnosis, Differential;
Female;
Fluorescein Angiography;
Follow-Up Studies;
Fundus Oculi;
Humans;
Interleukin-8/metabolism;
Intravitreal Injections;
Microscopy, Acoustic;
Scleritis/*drug therapy/metabolism/pathology;
Vascular Endothelial Growth Factor A/metabolism
- From:Korean Journal of Ophthalmology
2011;25(4):282-284
- CountryRepublic of Korea
- Language:English
-
Abstract:
We report a case of posterior scleritis effectively managed with intravitreal bevacizumab. A 71-year-old woman was diagnosed with posterior scleritis. Although she was initially treated with systemic steroids, her clinical presentation deteriorated. She was then treated with a single intravitreal injection of bevacizumab and aqueous humor collection. The aqueous level of vascular endothelial growth factor prior to the intravitreal injection was 880.51 pg/mL, greater than that in the healthy control group (p < 0.001). One month later, the scleritis was completely resolved, and the patient remained stable during six months of follow-up. Intravitreal bevacizumab appears to be an effective adjuvant therapy for patients with posterior scleritis.
